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IFN-γ hasbeenusedinthetreatmentofIL-12Rβ1deﬁciencypatientswithdisseminatedBCGinfection(BCGosis),buttheoptimal
dose to reach eﬃcacy is notclear. We used IFN-γ in thetreatment of a2.7-year-old patient with IL-12Rβ1deﬁciency and refractory
BCG-osis. IFNγ was started at a dose of 50μg/m2 3 times per week. The dose was upgraded to 100mcg/m2 after 3 months,
then to 200mcg/m2 6 months afterwards. Serum mycobactericidal activity and lymphocytes number and function were evaluated
throughout the study. There was no clinical response to IFN-γ with 50 or 100μg/m2 doses. However, there was some response to
the 200μg/m2 dose with no additional adverse eﬀects. The serum mycobactericidal activity was not signiﬁcantly diﬀerent during
the whole treatment period. Lymphocytes proliferation in response to PHA was signiﬁcantly higher after 3 months of using the
highest dose as compared to the lowest dose. The tuberculin skin test reaction remained persistently negative. We conclude that in
a patient with IL-12Rβ1 deﬁciency, IFN-γ at a dose of 200μg/m2, but not at lower dosages, was found to have a noticeable clinical
eﬀect with no additional adverse eﬀects.
1.Introduction
Investigation of a human syndrome known as Mendelian
susceptibility to mycobacterial diseases (MSMD) (OMIM
209950) has, in the past 15 years, led to the identiﬁcation
of a series of genetic defects in the IL-12/IFN-γ axis. These
include defects in three autosomal genes controlling the
response to IFN-γ: IFNGR1, encoding the ligand binding,
ﬁrst chain of the IFN-γ receptor; IFNGR2, encoding the
signaling, second chain of the IFN-γ receptor; STAT1,
encoding the signal transducer and activator of transcription
1downstreamfromIFN-γ receptor.Theyalsoincludedefects
in two other autosomal genes controlling the production of
IFN-γ: IL12B, encoding IL-12p40 shared by IL-12 and IL-
23; IL12RB1, encoding the ﬁrst chain of the IL-12 and IL-23
receptor (IL-12Rβ1). In addition, there is one X-linked gene
that encodes nuclear factor-kB essential modulator (NEMO)
[1–3].
IL-12Rβ1 defect was ﬁrst described in 1998 [4]a n d
is the most common among the known genetic disorders
that predispose to mycobacterial infections. The spectrum
of infections reported in these patients is, however, sur-
prisingly narrow. These patients display selective suscep-
tibility to weakly virulent Mycobacteria,s u c ha se n v i r o n -
mental mycobacteria (EM) and live bacille Calmette-Gu´ erin
(BCG) vaccine (an attenuated substrain of Mycobacterium
bovis), and Salmonella. They showed almost no increased
susceptibility to other pathogens including other bacteria2 Clinical and Developmental Immunology
and ubiquitously distributed viruses and fungi [5]. Evidence
suggests that the immune system is redundant in its response
to many intracellular microorganisms. For other organisms
like varicella zoster virus, Th1 activation and IFN-γ pro-
d u c t i o nw a sf o u n dt ob es t i m u l a t e db yI F N - α not IL-12
[6].
In a very recent report, that included the largest cohort
of patients with IL-12Rβ1 deﬁciency (141 patients) [7], the
mean age of onset of the ﬁrst infection was 2.4 years. The
severity of the disease varied signiﬁcantly from subjects who
were asymptomatic until adulthood to patients who died
in early childhood from complications of the disease. The
mortality rate was 32% among symptomatic subjects and
the mean age of death was 7.5 years, mostly secondary to
BCGosis or EM disease.
InpatientswithIL-12Rβ1deﬁciencywhodonotrespond
to prolonged therapy with multiple anti-mycobacterial
drugs, the mycobacteria frequently develop resistance to
some of these medications. The management of those
patients subsequently becomes very diﬃcult and frequently
they will not recover using antimycobacterials alone. Since
the most important reason of those patients’ failure to
control mycobacterial infections is the inability of their T
cells and NK cells to produce IFN-γ in response to IL-12
stimulation,IFN-γ isanattractivecandidatetherapythatcan
be tried in those patients [8]. However, the optimal dose and
duration of using IFN-γ are not clear.
2.SubjectandMethods
2.1.StudyPatient. Ourpatientwasreferredtousat6months
of age with left axillary lymphadenitis that grew the vaccine
strain of Mycobacteriumbovis (BCG), a routine vaccine given
in day one of life in Saudi Arabia. There was no granuloma
formation on the lymph node biopsy. She was otherwise
well apart from intermittent fever and night sweats. Her
parents were not consanguineous but from the same tribe.
She had a 5-years-old brother who had left axillary BCGitis
in infancy that resolved promptly after treatment with
isoniazid alone for 6 months. She also had a 7-years-
old sister who has been completely healthy. She did not
respond to isoniazide and rifampicin. Sensitivity results then
showed that the organism was resistant to both, so she was
started on ethambutol 300mg OD, cycloserine 250mg OD,
and moxiﬂoxacin 200mg OD for which the organism was
sensitive. Meanwhile, immunological investigations revealed
that our patient’s lymphocytes have no IFN-γ production
in response to IL-12+BCG as compared to controls (those
investigations were performed in Dr. Casanova’s lab in
Paris. Her parents were travel controls). Her brother had a
similar cellular phenotype (i.e., no IFN-γ production after
BCG and BCG+IL-12 stimulation in whole-blood assay)
(Table 1). In addition, no cell surface-expressed IL12RB1
could be detected from their PHA-T cell blast (data not
shown). Genetic testing conﬁrmed that she and her brother
have homozygous 1336delC mutation in the IL12RB1 gene,
leading to complete IL12Rβ1 deﬁciency. Her sister was
functionally and genetically normal. To our knowledge this
Table 1: In vitro Lymphocytes’ IFN-γ production in diﬀerent
conditions.
Stimulant IFN-γ (pg/ml)
Control Father Mother Sister Brother Patient
Medium 0 62 62 0 0 0
BCG 738 202 68 47 35 0
BCG+IL12 44461 6000 4233 988 13 0
is the only family with this speciﬁc type of mutation to be
reported [7].
2.2. Study Plan. After parental consent, baseline and fol-
lowup investigations were obtained including CBC, ESR,
liver enzymes, lymphocytes subsets, and tuberculin skin
test (TST) every 3 months. Immunoglobulin levels, serum
mycobactericidal activity, and lymphocytes proliferation in
vitro were performed every 6 months.
The patient was seen in the clinic every 6 weeks. IFN-
γ-1b (Imukin, Boehringer Ingelheim) was started at a dose
of 50μg/m2 subcutaneously 3 times/week. If there is no
signiﬁcant response within 3 months the dose will be
doubled to 100mcg/m2, at the same frequency.
2.3. Cellular Studies. Blood samples were taken from the
patient before starting treatment with IFNγ (S1), 6 months
(S2) and 12 months (S3) after starting treatment. PBMCs
were isolated from whole blood by density centrifuga-
tion (Lymphoprep, Nycomed, Oslo, Norway) and assayed
for in vitro proliferative responses by the thymidine
incorporation method against phytohemagglutinin (PHA)
(Sigma, St. Louis, Mo.) and IL2 (R&D System, Abington,
UK).
The proliferation results are expressed as mean count per
minute of triplicate cultures for the antigen concentration
giving maximum response minus the mean count-per-
minute values for 12 wells without antigen (medium only).
2.4. Serum Mycobactericidal Assay. Two specimens of the
patient’s serum were collected at 6 months and 12 months
of the study period, 2 hours after anti-mycobacterial drug
administration, to determine the serum inhibitory and
bactericidal titers against the patient’s mycobacterial isolate
as well as mycobacterium bovis BCG vaccine strain (Statens
S e r u mI n s t i t u t e ,C o p e n h a g e nS ,D e n m a r k )a n dm y c o b a c -
terium tuberculosis H37RV reference strain (ATCC, Atlanta,
GA, USA), as previously described [9].
3. Results
Our patient was started on IFN-γ a tad o s eo f5 0μg/m2 three
times a week in addition to her anti-mycobacterial medica-
tions as above (Figure 1). Three months later, the patient’s
conditionwasslightlyworse,soethionamide250mgODwas
added to her drug regimen and IFN-γ dose was upgradedClinical and Developmental Immunology 3
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Figure 1: Time line of the patient’s course. Above are the changes in medications and below are the changes in clinical condition from the
beginning of IFN-γ introductions till the patients’ death 15 months later.
to 100μg/m2 three times a week. Six months from the
beginning of the study her clinical condition continued
to worsen and she developed a left chest wall abscess. At
that time amikacin was added to her drug regimen for 6
weeks only. She was continued on the same dose of IFN-
γ. Nine months from the beginning of the study there was
noclinicalimprovement.Shewasonfouranti-mycobacterial
medications as mentioned above. At this point the dose was
upgraded to 200μg/m2. One month later the enlarged lymph
nodes and the chest wall abscess started to discharge pus
that was positive for acid-fast bacilli on ZN stain and the
culture grew Mycobacterium bovis. The patient felt better
and the abscesses and the discharging lymph nodes healed.
One month later she developed right pleural eﬀusion, but
remained clinically stable. Cultures from the eﬀusion were
negative. After 12 months from the beginning of the study
we ran out of IFN-γ and the patient continued on her
usual anti-mycobacterial medications. She then started to
deteriorate gradually. Three months later she developed
massive pneumonia and died. The only adverse eﬀect from
IFN-γ therapy that was noted throughout the study at the
diﬀerent doses was fever (up to 39◦C )a n dl e t h a r g yu pt o
8 hours from giving the injection. Her CBC, liver enzymes,
lymphocyte subsets, and immunoglobulin levels were not
signiﬁcantly changed and her ESR ﬂuctuated between 80–
107mm/hr throughout the study period.
The spectrum of proliferative responses of T cell follow-
ing stimulation with PHA and IL-2 is shown in Figure 2.
The percent increase of T cell proliferation in response to
PHA (1:10 dilution) rose from 17% at baseline to 26% at
6 months of the study, reaching 32% at 12 months (P = .02)
after increasing the dose of IFN-γ to 200μg/m2. There was,
however, no change after IL-2 stimulation, where percent
increase of T cell proliferation was 20%, 18%, and 17% at
baseline, 6 months, and 12 months, respectively.
There was no signiﬁcant diﬀerence between the serum
mycobactericidal activity at 6 months and at 12 months.
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Figure 2: The percent increase in T cell proliferation stimulated
withPHAandIL2incontrolandthethreesamplesfromthepatient:
(S1) before treatment, (S2) 6 months after treatment (S3) 12
months after treatment. The percent increase in Sample, (S3) stim-
ulation with PHA was signiﬁcantly higher than the response before
treatment (S1) (P = .02), while no signiﬁcant diﬀerence with IL2.
4. Discussion
Our patient had a severe phenotype of IL-12Rβ1 deﬁciency.
In addition, the organism was resistant to anti-BCG antibi-
otics. Therefore, it was more stringent to try IFN-γ as a
therapeutic agent. IFN-γ was tried initially at a dose of
50μg/m2 3 times a week based on the experience of using
it in other conditions like chronic granulomatous disease
(CGD) [10]. However, it was not surprising that it did not
work at this concentration with our patient since, unlike
patients with CGD, she is not able to produce IFN-γ and
the pathophysiology of the disease is completely diﬀerent.
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(200μg/m2)maybeattributedtothismedication.Thiscould
be supported by the deterioration in the patient’s condition
after cessation of IFN-γ. Since there was no diﬀerence in the
mycobactericidal activity between 6 months and 12 months
of the study period, the changes in the patient’s clinical
condition are unlikely to be due to the anti-mycobacterial
medications.
The increase in the lymphocyte proliferation in response
to PHA at 12 months as compared to 0 and 6 months
may be secondary to indirect stimulation of the patient’s
lymphocytes with the high-dose IFN-γ. However, the per-
sistently negative tuberculin skin test suggests that IFN-γ
therapy did not improve speciﬁc DTH to mycobacterial PPD
antigens. Since there were no additional adverse eﬀects with
the200μg/m2 doseofIFN-γ,ourexperiencewiththispatient
may encourage physicians to start directly with this dose
especially when there is no good response to maximum anti-
mycobacterial therapy after few months of treatment.
Achieving clinical resolution is very important in the
management of patients with IL-12Rβ1 deﬁciency and
BCGosis.PatientswithBCGdiseaserarelyhaverecurrenceor
develop EM disease, if they responded to multidrug antibi-
otic treatment [7]. On the other hand, patients frequently
develop recurrence of salmonellosis, sometimes involving
the same serotype. Interestingly, more than a quarter of
the genetically aﬀected siblings remain asymptomatic. This
strongly suggests that the IL-12 pathway is redundant for
the primary immune response against Mycobacteria and
Salmonella in a substantial proportion of patients.
IFN-γ was tried in some patients with IL-12Rβ1d e ﬁ -
ciency and BCGosis. There are only two reports of three
patients where IFN-γ was tried. The ﬁrst report includes 2
patients with BCGosis treated with IFN-γ for 18 months in
addition to antimycobacterials [11]. One patient survived
and the other died. The patient who responded had main-
tained a normal number of Th cells during treatment and
had good proliferative response to mycobacterial antigens
in vitro compared to the other patient. The second report
included one patient who had BCGosis for 13 years and
failed multiple ﬁrst- and second-line antimycobacterials. She
was having chronic diarrhea and her serum showed no in
vitro bactericidal nor bacteriostatic activity against BCG. She
fully recovered when IFN-γ was used for one year plus the
addition of intravenous anti-mycobacterial treatment to her
regimen [9]. Two other patients with similar presentation
were treated similarly by the same group and did well (direct
communication with Dr. Rosenzweig).
InmanycountriesaroundtheworldBCGvaccineisgiven
at birth or few months afterword. In Saudi Arabia, BCG
vaccine is given in day 1 of life. This was mainly because
of high incidence (243/100,000 in 1978) and problems
with compliance with vaccination schedule. Subsequently,
the incidence dropped to 90/100,000 in 1990 and now
11/1000,000 (Ministry of Health statistics). Recent studies
showed that giving BCG vaccine at birth induces signiﬁcant
mycobacterial immune response as early as 2 months of life.
When this response was tested at about 9 months of age it
was found to be maintained and comparable to infants who
received the vaccine at 2 or 4.5 months of life [12, 13].
In conclusion, in one patient with IL-12Rβ1 deﬁciency,
IFN-γ at a dose of 200μg/m2, but not at lower dosages, was
found to have a positive clinical eﬀect with no additional
adverse eﬀects. This medication holds promise in the
management of such patients especially if used early in the
course of disease. Multicenter studies are needed to establish
the eﬀectiveness, dose, and duration of IFN-γ treatment on a
large number of patients.
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